Mikhail Yu. Drokov

Mikhail Yu. Drokov

Auto-generated profile, based on publicly available information

Mikhail Yu. Drokov

National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2015 in Leukemia
Verified
Journal Article
Closed access
PDF file
EFE E Fink
E E Fink
SMS Mannava
S Mannava
ABA Bagati
A Bagati
ABAnna Bianchi-Smiraglia
Anna Bianchi-Smiraglia
JNJ R Nair
J R Nair
MNMikhail Nikiforov
Mikhail Nikiforov

25 October 2018 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
IMIvan Moiseev
Ivan Moiseev
TTTatyana Tsvetkova
Tatyana Tsvetkova
MAMahmoud Aljurf
Mahmoud Aljurf
RARanda M Alnounou
Randa M Alnounou
JBJanet Bogardt
Janet Bogardt
GBGrzegorz Wladyslaw Basak
Grzegorz Wladyslaw Basak

10 April 2018 in Stem Cells International
Verified
Journal Article
Open access
PDF file
NPNataliya Petinati
Nataliya Petinati
NDNina Drize
Nina Drize
NSNatalia Sats
Natalia Sats
NRNatalya Risinskaya
Natalya Risinskaya
ASAndrey Sudarikov
Andrey Sudarikov
VSValeriy Savchenko
Valeriy Savchenko
Multipotent mesenchymal stromal cells (MSCs) participate in the formation of bone marrow niches for hematopoietic stem cells. Donor MSCs can serve as a source of recovery for niches in patients with graft failure (GF) after allogeneic bone marrow (BM) transplantation. Since only few MSCs reach the BM after intravenous injection, MSCs were implanted into the iliac spine. For 8 patients with GF after allo-BMT, another hematopoietic stem cell transplantation with simultaneous implantation of MSCs from their respective donors into cancellous bone was performed. BM was aspirated from the iliac crest of these patients at 1-2, 4-5, and 9 months after the intraosseous injection of donor MSCs. Patients’ MSCs were cultivated, and chimerism was determined. In 6 out of 8 patients, donor hematopoiesis was restored. Donor cells (9.4 ± 3.3%) were detected among MSCs. Thus, implanted MSCs remain localized at the site of administration and do not lose the ability to proliferate. These results suggest that MSCs could participate in the restoration of niches for donor hematopoietic cells or have an immunomodulatory effect, preventing repeated rejection of the graft. Perhaps, intraosseous implantation of MSCs contributes to the success of the second transplantation of hematopoietic stem cells and patient survival.

1 March 2017 in Leukemia Research
Verified
Journal Article
Closed access
MDMikhail Y. Drokov
Mikhail Y. Drokov
JDJulia O. Davydova
Julia O. Davydova
LKLarisa A. Kuzmina
Larisa A. Kuzmina
IGIrina V. Galtseva
Irina V. Galtseva
NKNikolay Kapranov
Nikolay Kapranov
VSValery G. Savchenko
Valery G. Savchenko

9 May 2022 in Transplant Infectious Disease
Verified
Journal Article
Closed access
MAMobil Akhmedov
Mobil Akhmedov
GKGalina Klyasova
Galina Klyasova
LKLarisa Kuzmina
Larisa Kuzmina
AFAnastasia Fedorova
Anastasia Fedorova
VVVera Vasilyeva
Vera Vasilyeva
EPElena Parovichnikova
Elena Parovichnikova

13 November 2016 in Biochemistry (Moscow)
Verified
Journal Article
Closed access
AVA. S. Vdovin
A. S. Vdovin
SFS. Y. Filkin
S. Y. Filkin
PYP. R. Yefimova
P. R. Yefimova
SSS. A. Sheetikov
S. A. Sheetikov
NKNikolay Kapranov
Nikolay Kapranov
VSV. G. Savchenko
V. G. Savchenko
Patients undergoing allogeneic hematopoietic stem cell transplantation have a high risk of cytomegalovirus reactivation, which in the absence of T-cell immunity can result in the development of an acute inflammatory reaction and damage of internal organs. Transfusion of the virus-specific donor T-lymphocytes represents an alternative to a highly toxic and often ineffective antiviral therapy. Potentially promising cell therapy approach comprises transfusion of cytotoxic T-lymphocytes, specific to the viral antigens, immediately after their isolation from the donor's blood circulation without any in vitro expansion. Specific T-cells could be separated from potentially alloreactive lymphocytes using recombinant major histocompatibility complex (MHC) multimers, carrying synthetic viral peptides. Rapid transfusion of virus-specific T-cells to patients has several crucial advantages in comparison with methods based on the in vitro expansion of the cells. About 30% of hematopoietic stem cell donors and 46% of transplant recipients at the National Research Center for Hematology were carriers of the HLA-A*02 allele. Moreover, 94% of Russian donors have an immune response against the cytomegalovirus (CMV). Using recombinant HLA-A*02 multimers carrying an immunodominant cytomegalovirus peptide (NLV), we have shown that the majority of healthy donors have pronounced T-cell immunity against this antigen, whereas shortly after the transplantation the patients do not have specific T-lymphocytes. The donor cells have the immune phenotype of memory cells and can be activated and proliferate after stimulation with the specific antigen. Donor lymphocytes can be substantially enriched to significant purity by magnetic separation with recombinant MHC multimers and are not activated upon cocultivation with the antigen-presenting cells from HLA-incompatible donors without addition of the specific antigen. This study demonstrated that strong immune response to CMV of healthy donors and prevalence of HLA-A*02 allele in the Russian population make it possible to isolate a significant number of virus-specific cells using HLA-A*02-NLV multimers. After the transfusion, these cells should protect patients from CMV without development of allogeneic immune response.